Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19

Set Alert for Coronavirus COVID-19

Boehringer Ingelheim Boosts COVID-19 Efforts As Jardiance Continues To Impress

Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.

Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets

The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.

Coronavirus Update: BMS Expands Medicine Program, Cancer Research UK Cuts Funding

Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.

Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso

The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

AZ and GSK Dip Into Diagnostics To Support COVID-19 UK Tests

The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Dissecting The Impact: Chi-Med Details Coronavirus Experience

CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical. 

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

How Novartis Is Helping Staff Through COVID-19 Crisis

Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.

Interview: Izana Tests GM-CSF Drug For Coronavirus

The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.

Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine

Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.

Amgen, Adaptive Partner In COVID-19 Neutralizing Antibody R&D Effort

The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.

UsernamePublicRestriction

Register